Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Depreciation & Amortization (CF): 2016-2020

Historic Depreciation & Amortization (CF) for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Dec 2020 value amounting to $690,000.

  • Rhythm Pharmaceuticals' Depreciation & Amortization (CF) was N/A to $315,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $690,000 for FY2020, which is 17.27% down from last year.
  • Rhythm Pharmaceuticals' Depreciation & Amortization (CF) amounted to $690,000 in FY2020, which was down 17.27% from $834,000 recorded in FY2019.
  • Over the past 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) peaked at $834,000 during FY2019, and registered a low of $144,000 during FY2016.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Depreciation & Amortization (CF) value was $690,000 (recorded in 2020), while the average stood at $655,333.
  • In the last 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) spiked by 98.21% in 2018 and then dropped by 17.27% in 2020.
  • Over the past 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $144,000 in 2016, then skyrocketed by 54.86% to $223,000 in 2017, then spiked by 98.21% to $442,000 in 2018, then soared by 88.69% to $834,000 in 2019, then fell by 17.27% to $690,000 in 2020.